Pdlg Retirees: This Passive-Income Stream of $10,250/Year Is Real and it Grows
Whether you are planning your retirementor have a long-term financial goal, picking the right investments from the Canadian stock market can make it possible. You can take several possible approaches to stock market investing. If you seek rapid growth, the TSX offers plenty of high-risk and high-reward equity securities to consider. For those in it for more secure long-term growth, there are opportunities to play the slow and steady game.While a conservative approach means losing out on rapid growth, it gives you more certainty. For risk-averse investors with a long investment horizon, it is not a weak approach to stock market investing.If you are looking for steady stocks stanley cup that can deliver more reliable long-term wealth growth, there are a couple of Canadian dividend stocksyou can add to your self-directed port stanley cup folio.Royal Bank of CanadaRoyal Bank of Canada TSX:RY is the largest Canadian stock on the TSX in market capitalization. Bo stanley cups uk asting a $171.53 billion market capitalization, it is Jqau Why Canopy Growth Stock Could Double in 2024
Valeant Pharmaceuticals Intl Inc. TSX:VRX NYSE:VRX reported unaudited results for the fou stanley cups uk rth quarter of 2015, and they were ugly to say the least. We ;ll ta stanley mug ke a closer look at the numbers and also look at why the stock shouldn t be bought at any price.Very disappointing numbersIf there was any good news, it that Valeant generated US$2.8 billion during the fourth quarter. Otherwise, there is nothing positive to report.Valeant s Q4 earnings per share EPS came in at US$2.50, which was US$0.11 below consensus estimates. But the real bad news came when the company gave its updated guidance. For the year 2016, Va stanley mugg leant expects revenue between US$11 billion and US$11.2 billion, down from prior guidance of US$12.5-12.7 billion. EPS is expected to come in at US$9.50-10.50, again, down from prior guidance, which was US$13.25-13.75.Even more worryingly, Valeant forecasted US$6.2-6.6 billion in adjusted EBITDA in the 12 months following March 31, but then lowered that estimate to
